IMRX Share Price Performance
US$5.74
4.01 (231.79%)
Price US$5.74
Share Pricen/a
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
Nov 22
Immuneering Corporation Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
IMRX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Immuneering Corporation Key Details
About IMRX
- Founded
- 2008
- Employees
- 54
- CEO
- WebsiteView website
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
